GlassScriptPhysician profile
Sundas Khan
NPI 1548764756
$5,046.57
in general payments reported to CMS, 2019-2025
46 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.15 · 2022: $1,027 · 2023: $1,977 · 2024: $1,848 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,108 · Long Term Medical Supply Or Device Loan: $499 · Education: $290 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,108.40 |
| Long Term Medical Supply Or Device Loan | $498.50 |
| Education | $290.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $803.19 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $472.19 | 2021-2024 | Enhertu, Calquence, Lynparza |
| Seagen INC. | $289.90 | 2021-2023 | Adcetris, Tukysa |
| Astellas Pharma US INC | $286.80 | 2023-2024 | Xospata, Xtandi |
| Genzyme Corporation | $281.88 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $244.93 | 2021-2024 | Opdivo, Opdualag |
| Eisai INC. | $198.74 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $190.59 | 2023-2024 | Soliris, Ultomiris |
| Ipsen Biopharmaceuticals, INC | $178.43 | 2023-2024 | Onivyde, Somatuline Depot, Tazverik |
| Jazz Pharmaceuticals INC. | $174.89 | 2023 | |
| Lilly USA, LLC | $137.76 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $132.41 | 2023-2024 | Venclexta, Tecentriq, Alecensa |
| Incyte Corporation | $130.09 | 2022-2023 | Pemazyre, Monjuvi |
| Pfizer INC. | $119.92 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sundas Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.